| Insiders | Shares | % | Avg Price | Total $ | |
|---|---|---|---|---|---|
| Buys | 1 | +1,025,490 | 85% | $11.96 | +$12,261,931 |
| Sells | 4 | -187,933 | 15% | $24.87 | -$4,673,751 |
| Net | -3 | +837,557 | 69% | +$7,588,180 |
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Mark Hollywood | ZYME | Common Stock | Sale | -4.4% | $138,762 | $22.67 | -6,120 | 132,913 | 12 Jan 2026 | Direct |
| Mark Hollywood | ZYME | Common Stock | Options Exercise | 14.6% | 17,666 | 139,033 | 12 Jan 2026 | Direct | ||
| Mark Hollywood | ZYME | Performance Stock Unit | Award | 66,000 | 66,000 | 12 Jan 2026 | Direct | |||
| Mark Hollywood | ZYME | Restricted Stock Unit | Award | 47,000 | 47,000 | 12 Jan 2026 | Direct | |||
| Mark Hollywood | ZYME | Stock Option (Right to Buy) | Award | 70,000 | 70,000 | 12 Jan 2026 | Direct | |||
| Mark Hollywood | ZYME | Restricted Stock Unit | Options Exercise | -33.3% | -17,666 | 35,334 | 12 Jan 2026 | Direct | ||
| Brian N. Cherry | ZYME | Restricted Stock Unit | Award | 15,400 | 15,400 | 12 Jan 2026 | Direct | |||
| Brian N. Cherry | ZYME | Stock Option (Right to Buy) | Award | 23,000 | 23,000 | 12 Jan 2026 | Direct | |||
| Smith Jeffrey T. L. | ZYME | Common Stock | Sale | -25.8% | $211,090 | $22.67 | -9,310 | 26,708 | 12 Jan 2026 | Direct |
| Smith Jeffrey T. L. | ZYME | Common Stock | Options Exercise | 96.3% | 17,666 | 36,018 | 12 Jan 2026 | Direct | ||
| Smith Jeffrey T. L. | ZYME | Restricted Stock Unit | Options Exercise | -33.3% | -17,666 | 35,334 | 12 Jan 2026 | Direct | ||
| Gregory Austin Ciongoli | ZYME | Restricted Stock Unit | Award | 7,700 | 7,700 | 12 Jan 2026 | Direct | |||
| Gregory Austin Ciongoli | ZYME | Stock Option (Right to Buy) | Award | 11,500 | 11,500 | 12 Jan 2026 | Direct | |||
| Kelvin Neu | ZYME | Restricted Stock Unit | Award | 7,700 | 7,700 | 12 Jan 2026 | Direct | |||
| Kelvin Neu | ZYME | Stock Option (Right to Buy) | Award | 11,500 | 11,500 | 12 Jan 2026 | Direct | |||
| Robert E. Landry | ZYME | Restricted Stock Unit | Award | 7,700 | 7,700 | 12 Jan 2026 | Direct | |||
| Robert E. Landry | ZYME | Stock Option (Right to Buy) | Award | 11,500 | 11,500 | 12 Jan 2026 | Direct | |||
| Alessandra Cesano | ZYME | Restricted Stock Unit | Award | 7,700 | 7,700 | 12 Jan 2026 | Direct | |||
| Alessandra Cesano | ZYME | Stock Option (Right to Buy) | Award | 11,500 | 11,500 | 12 Jan 2026 | Direct | |||
| Carlos Campoy | ZYME | Restricted Stock Unit | Award | 7,700 | 7,700 | 12 Jan 2026 | Direct | |||
| Carlos Campoy | ZYME | Stock Option (Right to Buy) | Award | 11,500 | 11,500 | 12 Jan 2026 | Direct | |||
| Susan Mahony | ZYME | Restricted Stock Unit | Award | 7,700 | 7,700 | 12 Jan 2026 | Direct | |||
| Susan Mahony | ZYME | Stock Option (Right to Buy) | Award | 11,500 | 11,500 | 12 Jan 2026 | Direct | |||
| Paul Andrew Moore | ZYME | Common Stock | Sale | -16.5% | $216,759 | $22.67 | -9,560 | 48,497 | 12 Jan 2026 | Direct |
| Paul Andrew Moore | ZYME | Common Stock | Options Exercise | 43.7% | 17,666 | 58,057 | 12 Jan 2026 | Direct | ||
| Paul Andrew Moore | ZYME | Performance Stock Unit | Award | 66,000 | 66,000 | 12 Jan 2026 | Direct | |||
| Paul Andrew Moore | ZYME | Restricted Stock Unit | Award | 47,000 | 47,000 | 12 Jan 2026 | Direct | |||
| Paul Andrew Moore | ZYME | Stock Option (Right to Buy) | Award | 70,000 | 70,000 | 12 Jan 2026 | Direct | |||
| Paul Andrew Moore | ZYME | Restricted Stock Unit | Options Exercise | -33.3% | -17,666 | 35,334 | 12 Jan 2026 | Direct | ||
| Kenneth Galbraith | ZYME | Common Stock | Sale | -11.8% | $689,819 | $22.67 | -30,424 | 226,842 | 12 Jan 2026 | Direct |
| Kenneth Galbraith | ZYME | Common Stock | Options Exercise | 33.1% | 64,000 | 257,266 | 12 Jan 2026 | Direct | ||
| Kenneth Galbraith | ZYME | Performance Stock Unit | Award | 222,000 | 222,000 | 12 Jan 2026 | Direct | |||
| Kenneth Galbraith | ZYME | Restricted Stock Unit | Award | 144,000 | 144,000 | 12 Jan 2026 | Direct | |||
| Kenneth Galbraith | ZYME | Stock Option (Right to Buy) | Award | 216,000 | 216,000 | 12 Jan 2026 | Direct | |||
| Kenneth Galbraith | ZYME | Restricted Stock Unit | Options Exercise | -33.3% | -64,000 | 128,000 | 12 Jan 2026 | Direct | ||
| Leone D. Patterson | ZYME | Common Stock | Award | 459 | 459 | 06 Jan 2026 | Direct | |||
| Smith Jeffrey T. L. | ZYME | Common Stock | Sale | -36.5% | $264,471 | $25.10 | -10,538 | 18,352 | 05 Jan 2026 | Direct |
| Smith Jeffrey T. L. | ZYME | Common Stock | Options Exercise | 225% | 20,000 | 28,890 | 05 Jan 2026 | Direct | ||
| Smith Jeffrey T. L. | ZYME | Restricted Stock Unit | Options Exercise | -50% | -20,000 | 20,000 | 05 Jan 2026 | Direct | ||
| Kenneth Galbraith | ZYME | Common Stock | Sale | -25.6% | $1,363,841 | $25.10 | -54,343 | 158,286 | 05 Jan 2026 | Direct |
| Kenneth Galbraith | ZYME | Common Stock | Options Exercise | 103.4% | 114,334 | 224,952 | 05 Jan 2026 | Direct | ||
| Kenneth Galbraith | ZYME | Restricted Stock Unit | Options Exercise | -100% | -114,334 | 0 | 05 Jan 2026 | Direct | ||
| Paul Andrew Moore | ZYME | Common Stock | Sale | -39.2% | $504,699 | $25.10 | -20,110 | 31,212 | 05 Jan 2026 | Direct |
| Paul Andrew Moore | ZYME | Common Stock | Options Exercise | 264.6% | 37,168 | 51,212 | 05 Jan 2026 | Direct | ||
| Paul Andrew Moore | ZYME | Restricted Stock Unit | Options Exercise | -100% | -37,168 | 0 | 05 Jan 2026 | Direct | ||
| Kenneth Galbraith | ZYME | Common Stock | Sale | -26.3% | $1,284,311 | $27.02 | -47,528 | 133,275 | 22 Dec 2025 | Direct |
| Kenneth Galbraith | ZYME | Common Stock | Options Exercise | 123.8% | 100,000 | 180,803 | 22 Dec 2025 | Direct | ||
| Kenneth Galbraith | ZYME | Restricted Stock Unit | Options Exercise | -100% | -100,000 | 0 | 22 Dec 2025 | Direct | ||
| Gregory Austin Ciongoli | ZYME | Common Stock | Award | 564.6% | 415,000 | 488,500 | 12 Aug 2025 | Direct | ||
| Gregory Austin Ciongoli | ZYME | Stock Option (Right to Buy) | Award | 62,000 | 62,000 | 11 Aug 2025 | Direct |